United States Patent 10,912,765: Oxymetazoline Eyelid-Lifting Claims, Patent Scope, and Competitive Landscape

U.S. Patent No. 10,912,765 protects a method of using approximately 0.1% oxymetazoline ophthalmic composition to increase the vertical separation between the upper and lower eyelids in subjects with acquired blepharoptosis or a similar eyelid-opening deficit. The patent does not claim oxymetazoline itself, a composition containing oxymetazoline, or every ophthalmic use of the drug. Its principal protection is a narrow method-of-use claim tied to a specific concentration, ocular administration, therapeutic result, and patient exclusions.

The patent is commercially relevant to Upneeq, the oxymetazoline hydrochloride ophthalmic solution approved by the FDA for acquired blepharoptosis in adults. The principal generic-entry risk is a Paragraph IV challenge directed at the method claims and any related formulation or manufacturing patents listed for the approved product.

What does U.S. Patent 10,912,765 protect?

The independent claims protect administration of a composition containing about 0.1 weight percent oxymetazoline to the exterior surface of the eye to increase vertical eyelid separation.

Claim element	Required limitation
Active ingredient	Oxymetazoline
Concentration	About 0.1 weight percent
Vehicle	Ophthalmologically acceptable carrier
Route	Administration to the exterior surface of the eye
Result	Increased vertical separation of the upper and lower eyelids
Patient exclusions	No allergic ocular condition calling for oxymetazoline treatment; no eyelid swelling; no prior refractive eye surgery
Dosage limitations	Dependent claims cover a single drop and once-daily or at-least-once-daily dosing
Quantified response	At least 5%, at least 10%, at least 0.5 mm, or at least 1 mm increase

Claim 1 is the broadest independent claim because it does not require a particular measured degree of eyelid opening. It requires only an effective amount and an increase in vertical separation.

Claim 9 is a second independent method claim with substantially similar scope. Its wording is potentially important because it recites administration of a composition comprising approximately 0.1% oxymetazoline in an ophthalmologically acceptable carrier, while retaining the same therapeutic objective and patient exclusions.

How do the claims differ from one another?

Claims 1 and 9 establish two overlapping independent claim paths. Claims 2 through 8 depend from claim 1.

Claim	Additional limitation	Commercial significance
1	Increase in vertical lid separation; 0.1% oxymetazoline; specified exclusions	Primary broad method claim
2	At least 5% increase	Covers a measurable response threshold
3	At least 10% increase	Narrower efficacy threshold
4	At least 0.5 mm increase	Absolute measurement threshold
5	At least 1 mm increase	More demanding absolute threshold
6	Pharmaceutically acceptable oxymetazoline salt	Covers oxymetazoline hydrochloride and potentially other acceptable salts
7	Single-drop administration	Relevant to commercial single-use or multidose dropper products
8	Once daily or at least once daily	Closely tracks the labeled Upneeq dosing regimen
9	Independent composition-based method wording	Provides a separate infringement route

The dependent claims create fallback positions if a court narrows the broad efficacy language in claim 1. A product that produces a 0.5 mm or 1 mm improvement could fall within claims 4 or 5 even if disputes arise over what constitutes a clinically meaningful increase.

What is the claim scope of “about 0.1 weight percent”?

“About 0.1 weight percent” is a range limitation, not necessarily an exact 0.100% requirement. Its construction would depend on the specification, prosecution history, analytical precision, and technical meaning of “about” in ophthalmic formulation practice.

A commercial product containing 0.1% oxymetazoline hydrochloride would be the clearest target. A formulation containing a materially different concentration could avoid literal infringement, but the doctrine of equivalents could remain relevant if the concentration difference does not materially alter the claimed therapeutic function.

The salt limitation in claim 6 is significant. Upneeq is marketed as oxymetazoline hydrochloride ophthalmic solution. A generic using the same salt would likely satisfy claim 6 if all other limitations are met. A different oxymetazoline salt could still infringe claim 1 because claim 1 recites oxymetazoline generally, while claim 6 expressly confirms salt coverage.

What patient populations are excluded from the patent claims?

The claims expressly exclude three categories:

Subjects with an allergic ocular condition calling for treatment with oxymetazoline.
Subjects with eyelid swelling.
Subjects who have undergone refractive eye surgery.

These negative limitations narrow the claimed patient population. They distinguish the patented use from older uses of oxymetazoline for ocular allergy, redness, swelling, or postoperative conditions.

The exclusions create both a validity and infringement issue. A generic applicant could argue that the exclusions were added to distinguish prior art or that they create uncertainty in identifying the covered population. The patent holder would likely argue that the commercial treatment population, acquired blepharoptosis patients without those conditions, falls squarely within the claims.

The exclusions also limit the patent’s reach. A competing oxymetazoline product used exclusively for allergic conjunctivitis, ocular redness, or postoperative swelling would not necessarily practice the claimed method.

Does the patent claim acquired blepharoptosis directly?

The supplied claims do not expressly use the term “acquired blepharoptosis.” They claim an increase in vertical separation of the upper and lower lids in a subject in need thereof.

That drafting approach can be broader than a diagnosis-specific claim. It may cover patients whose reduced eyelid aperture results from acquired ptosis or another nonexcluded condition, provided the treatment produces the claimed eyelid-opening result.

The phrase “subject in need thereof” is likely to be interpreted in connection with the specification and the approved therapeutic use. It does not automatically cover cosmetic eyelid opening in every healthy person. The clinical purpose, patient condition, and administration context would be relevant in determining infringement.

What formulations are protected by U.S. Patent 10,912,765?

The patent protects a method using a composition with:

Approximately 0.1% oxymetazoline by weight;
An ophthalmologically acceptable carrier; and
Administration to the exterior surface of the eye.

The claims do not require a particular preservative, buffer, pH, tonicity agent, viscosity modifier, container, or device. A generic formulation could therefore infringe even if it changes inactive ingredients, provided the formulation remains within the claimed concentration and carrier limitations.

The claims also do not require a specific commercial container. Claim 7, however, creates direct exposure for a single-drop product. A unit-dose product administered once daily could implicate both claims 7 and 8.

Separate formulation or device patents could provide additional protection for preservative systems, container closure systems, stability profiles, drop size, or manufacturing processes. Those rights must be analyzed independently because they are not established by the supplied claims.

What is the likely Orange Book status of the patent?

U.S. Patent 10,912,765 is associated with the oxymetazoline ophthalmic product Upneeq and is the type of method-of-use patent that may be listed in the FDA Orange Book against an approved drug product. Orange Book listing is determined by FDA rules and the NDA holder’s patent submissions. Listing does not establish that the patent is valid, enforceable, or infringed.

A listed method-of-use patent can require a generic applicant to make a Paragraph IV certification if the applicant seeks approval for a use that falls within the patent claims. A generic applicant may instead submit a section viii statement and omit the patented use if the FDA-approved labeling can support a carve-out.

For this patent, a clean section viii strategy would be difficult if the generic seeks approval for the same 0.1% oxymetazoline eyelid-lifting indication. The commercial value of the product depends on that indication, making a Paragraph IV certification more likely than a purely label-based carve-out.

When does exclusivity for oxymetazoline ophthalmic solution expire?

Oxymetazoline is an old active ingredient, so the product did not receive five-year new chemical entity exclusivity for the active moiety. Upneeq received FDA approval in July 2020 for acquired blepharoptosis in adults. Any three-year exclusivity based on new clinical investigations would have expired in 2023, subject to the exact scope of the FDA exclusivity code and approval date.

Regulatory exclusivity and patent protection are separate. Expiration of FDA exclusivity did not eliminate the method-of-use patent or any later-issued formulation, manufacturing, or delivery-system patents.

Protection type	Relevance to Upneeq
New chemical entity exclusivity	Unavailable for an old active ingredient
Three-year clinical investigation exclusivity	Potentially relevant to the 2020 approval; generally ended in 2023
Patent protection	Depends on patent family, listed patents, term adjustment, and enforceability
Pediatric exclusivity	Applies only if FDA granted it for qualifying studies
Orphan exclusivity	Not indicated for the adult acquired blepharoptosis approval

When does U.S. Patent 10,912,765 expire?

The exact expiration date cannot be derived from the issued claim text alone. It depends on the earliest effective nonprovisional filing date, any patent-term adjustment, terminal disclaimer, patent-term extension, and the complete priority chain.

The controlling framework is generally 35 U.S.C. §154, which provides a patent term measured from the earliest effective U.S. nonprovisional filing date, subject to statutory adjustments. A patent’s expiration date should therefore be taken from the USPTO patent record and Orange Book listing rather than calculated solely from the issue date.

The patent issued on January 12, 2021. Its enforceability began on issuance, subject to any applicable pre-issuance activity and statutory remedies. A patent term extending into the mid-2030s would be commercially consistent with a nonprovisional filing in the mid-2010s, but the authoritative date is the USPTO term record.

What are the main validity risks?

The most important validity issues are claim construction, written description, enablement, indefiniteness, and prior-art separation.

Prior art and obviousness

Oxymetazoline was already known for nasal decongestion, ocular redness, and allergic ocular conditions. The patent’s inventive distinction is the use of approximately 0.1% oxymetazoline to increase eyelid separation in a defined patient population.

An obviousness challenge could combine:

Prior oxymetazoline ophthalmic use;
Knowledge of alpha-adrenergic effects on Müller’s muscle or eyelid elevation;
Clinical literature concerning ptosis;
Earlier ocular decongestant formulations; and
Evidence that the claimed concentration and dosing were routine.

The patent holder would likely rely on the claimed clinical result, patient exclusions, dosing performance, and any unexpected improvement in eyelid aperture or safety.

Indefiniteness

Potentially disputed terms include:

“About 0.1 weight percent”;
“Effective amount”;
“Subject in need thereof”;
“Vertical separation”;
“Exterior surface of an eye”; and
“At least once a day.”

The quantified claims provide more objective boundaries than claim 1. Claims 4 and 5, for example, use millimeter thresholds that may be easier to test clinically than the unquantified “increase” in claim 1.

Written description and enablement

The specification must support the full breadth of the claimed patient population and formulations. If the disclosure demonstrates efficacy only in a narrow clinical group, a challenger could argue that claims covering all subjects satisfying the exclusions lack adequate support.

The claims are method claims, so enablement also depends on whether the patent teaches clinicians how to achieve the claimed result across the full scope without undue experimentation.

Which companies could challenge the patent?

Potential challengers include manufacturers seeking an abbreviated new drug application for 0.1% oxymetazoline ophthalmic solution. Relevant companies would be established ophthalmic generic manufacturers and firms with experience in Paragraph IV litigation, including companies such as Apotex, Dr. Reddy’s Laboratories, Hikma, Sandoz, Teva, Viatris, and Zydus.

No company should be treated as an actual challenger without a filed Paragraph IV notice, ANDA litigation complaint, or public settlement record. A commercial generic applicant may challenge the patent privately through an ANDA certification before litigation becomes public.

A Paragraph IV case would likely focus on whether the proposed label induces the claimed use, whether the patient exclusions are present, and whether the generic’s 0.1% composition and dosing regimen meet the claim limitations.

What generic launch scenarios exist?

Early launch after Paragraph IV litigation

If a generic applicant files a valid Paragraph IV certification and the patent holder sues within 45 days, FDA approval may be subject to a statutory 30-month stay. The generic could launch earlier if the patent is invalidated, found not infringed, disclaimed, or settled on terms allowing entry.

Label carve-out

A section viii carve-out could omit the patented eyelid-lifting indication. That strategy would have limited commercial value because the approved product’s principal market is acquired blepharoptosis.

Settlement

A settlement could establish a negotiated entry date, supply arrangement, license, or other commercial terms. No settlement should be assumed without a publicly filed agreement or court record.

At-risk launch

A generic could launch before final resolution, exposing the applicant to damages, an injunction, and potential enhanced damages if infringement is found. Method-of-use patents can create substantial risk where the proposed label expressly directs the patented administration and patient population.

How strong is the patent estate?

U.S. Patent 10,912,765 has meaningful commercial strength because it aligns closely with the approved Upneeq use: 0.1% oxymetazoline ophthalmic solution administered to increase eyelid opening. Its weaknesses are the narrow active ingredient and concentration requirements, the potentially contestable negative limitations, and the dependence on clinical-result proof.

The estate is stronger if related patents separately protect:

The formulation;
Oxymetazoline hydrochloride ophthalmic stability;
Dropper or unit-dose delivery;
Manufacturing processes;
Specific dosing schedules;
Treatment of acquired blepharoptosis; and
Commercial packaging or device systems.

The patent is weaker if it is the only enforceable patent covering the commercial product and if the generic can formulate outside the “about 0.1%” range while preserving clinical efficacy.

What is the competitive landscape for oxymetazoline eyelid therapy?

Upneeq is differentiated from traditional surgical and mechanical treatments for ptosis. Its competitive alternatives include ptosis repair surgery, eyelid crutches, apraclonidine-based approaches, and off-label adrenergic ophthalmic products.

Oxymetazoline’s commercial advantage is a non-surgical, once-daily topical treatment. Its limitations include the need for continued dosing, variable response, ocular adverse effects, contraindications, and competition from lower-cost compounded or off-label products.

For a generic entrant, the primary barrier is not active-ingredient access. Oxymetazoline is widely known and commercially available. The barrier is approval for the patented indication and the risk that the generic label, concentration, dosing, and clinical instructions will practice the asserted method.

Key Takeaways

U.S. Patent 10,912,765 is a method-of-use patent, not a composition patent covering oxymetazoline generally.
The core claim requires approximately 0.1% oxymetazoline, ophthalmic administration, increased vertical eyelid separation, and specified patient exclusions.
Claims 4 and 5 provide objective 0.5 mm and 1 mm efficacy thresholds.
Claim 7 covers single-drop administration, while claim 8 covers once-daily or more frequent dosing.
The claims closely track the approved Upneeq use for acquired blepharoptosis.
Oxymetazoline’s old active-ingredient status limits regulatory exclusivity, but does not eliminate patent barriers.
A generic seeking the same eyelid-lifting indication would face substantial Paragraph IV and inducement-to-infringe risk.
The patent’s ultimate commercial strength depends on its exact term, Orange Book listing, prosecution history, related patents, and any litigation or settlement record.

FAQs About U.S. Patent 10,912,765

Does U.S. Patent 10,912,765 cover oxymetazoline nasal spray?

No. The supplied claims require administration to the exterior surface of the eye and a resulting increase in vertical eyelid separation. Ordinary nasal use does not satisfy those limitations.

Can a generic avoid the patent by using a concentration other than 0.1%?

Possibly, but not automatically. A materially different concentration may avoid literal infringement, while the doctrine of equivalents and related patents could still create exposure.

Does the patent cover cosmetic use of oxymetazoline to enlarge the eye?

The claims require a subject in need thereof and exclude specific ocular conditions. Purely cosmetic use may fall outside the claims, but the answer depends on the facts, labeling, patient condition, and claim construction.

Is oxymetazoline hydrochloride covered by claim 6?

Yes. Claim 6 expressly covers a pharmaceutically acceptable salt of oxymetazoline. Oxymetazoline hydrochloride is the commercially relevant salt in Upneeq.

Can a compounded pharmacy freely prepare 0.1% oxymetazoline for eyelid opening?

No conclusion follows from compounding status alone. A compounded product and its use may still implicate method-of-use claims, although infringement analysis depends on the prescriber’s instructions, patient population, labeling, and applicable statutory exemptions.

References

[1] U.S. Patent No. 10,912,765. (2021). Methods for increasing vertical separation of the upper and lower lids of an eye using oxymetazoline. United States Patent and Trademark Office.

[2] U.S. Food and Drug Administration. (2020). Upneeq (oxymetazoline hydrochloride ophthalmic solution) prescribing information. FDA.

[3] U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

[4] Patent Act, 35 U.S.C. §§ 154, 271, 281, 355(j).

[5] U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. FDA.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Rvl Pharms	UPNEEQ	oxymetazoline hydrochloride	SOLUTION/DROPS;OPHTHALMIC	212520-001	Jul 8, 2020		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				METHOD OF TREATING BLEPHAROPTOSIS	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2012223615	⤷ Start Trial
Brazil	112013022094	⤷ Start Trial
Canada	2827285	⤷ Start Trial
China	103501771	⤷ Start Trial
Cyprus	1122565	⤷ Start Trial
Denmark	2680829	⤷ Start Trial
European Patent Office	2680829	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 10,912,765

Which drugs does patent 10,912,765 protect, and when does it expire?

Summary for Patent: 10,912,765